Q² Solutions a Quintiles Quest Joint Venture

Oncology solutions: Development support across the life cycle

Q² Solutions is an oncology development partner that understands the complexity of cancer – including the underlying biologic processes and clinically relevant lab technologies required for delivering valuable insights to shape better outcomes. With industry-leading expertise and innovative end-to-end lab services, Q² Solutions can support your oncology research from discovery to post-market.

in-house pathologists with extensive molecular and anatomic pathology expertise

Safety testing

- Anatomic and molecular pathology (IHC, ISH)
- Immunoassay
- Flow cytometry
- Genomics
- Circulating tumor cells
- CTLA4 and PD-1/PD-L1 immuno-oncology expertise and more

Learn more at www.Q2LabSolutions.com/central-laboratories



We offer bioanalytical, immunogenicity (ligand binding), ADME and specialty genomics (NGS, RNASeq) labs plus support for companion diagnostics studies for precision medicine.



of the Top 30 best-selling oncology products of 2016 Q² Solutions helped develop many **biomarkers** used today including BCR-Abl, ALK, BRAF, C-KIT, EGFR, KRAS, HER2, MET, PD-L1

>100 companion diagnostics development engagements

Q² Solutions has helped develop **54%** of all FDA-approved oncology precision medicine drugs since 2014

Q² Solutions has helped develop of all FDA-approved oncology pharmacogenomics products to date

Q² Solutions **56%** of **oncology biologic** helped develop **56%** drugs since 2011

Since 2011 we've provided services for



>890 oncology studies in 73 countries



involving **>155,000** patients

Actionable Insights for **Better Health**

A broad test menu including safety, esoteric and custom assays to meet the demands of your clinical program

Discipline	Methodology	Example biomarkers/assays
Safety testing hematology/ coagulation, special chemistry/ urinalysis	 Enzymatic analysis Colorimetry Turbidimetry Spectrophotometry Automated cell counting Leukocyte differential counting Conductivity and light scatter Chromatography Clotting time 	 Routine chemistry (including serum factors for TLS) Renal functions (eGFR, creatinine, cystatin C) Hepatic function (ALT/AST) Urinalysis Endocrinology Thyroid functions CBC WBC differential Reticulocytes HbA1c Prothrombin time, aPTT, Fibrinogen D-dimer, proteins S and C Von Willebrand factor
Anatomic and molecular pathology	 Tissue processing (FFPE, TMAs) Confirmatory diagnosis Immunohistochemistry, including immune score, H score, tumor proportion scores, assay specific scoring algorithm ISH/FISH/Dual ISH Molecular mutation assays Digital pathology, telepathology, image analysis, image repository, remote access Special stains Companion diagnostics 	 Lung panel (ALK, EGFR, MET) Breast panel (ER, PgR, Her2, Her3, pEGFR, pHer2, pHer3, PTEN) Lymphoma panel: CD20, CD45, CD3, CD5, CD23, CD10, BCL2, MUM1, Ki67) PD markers: pRb, pAKT, pERK ISH/FISH/Dual ISH assays: ALK, Her2 (breast and gastric carcinoma), EGFR, PIK3CA, CLL panel, FGF19, FGFR1/EBER ISH, MET Dual ISH, HPV CISH Mutations: PIK3CA, EGFR, HGF, ROS1, KRAS, BRAF
Immunoassay	 Manual or automated ELISA Multiplex ELISA (bead-based detection, biochips), including ultra low-volume, low-level detection (fmol range) 	 Immunogenicity assays Soluble tumor antigens (CA-125, CA-15-3, CA-19, CEA, HE4) Inflammatory and angiogenesis panels (e.g., IFNα TNF-α, IL1β IFNγ, VEGFs, Ang-2, etc.) Oncoproteins/ligands: HGF, FGFs, SCF, neuregulins, soluble receptors (VEGFR, FGFRs, sHER2)
Flow cytometry	 Light scatter and cellular fluorescence, including 10-color cytometers 	 MRD Panels (CLL, in vitro cytoxicity) B lymphocyte clonality (κ/λ) Immunophenotyping (T cell subsets – effector, memory, regulatory, Th17, Th1, Th2, T regs; MDSCs; B cell subsets – plasma cells, activation) Functionality and signaling: phosphoflow and cytokine secretion
Genomics	 Next-generation sequencing (from blood, bone marrow, FFPE, or frozen tissue) Bioinformatics and pipeline development Genotyping Microarrays CLIA NGS panels 	 Digital PCR and high multiplex gene expression (e.g. Nanostring) RNA sequencing Targeted exome sequencing DNA methylation analysis miRNA sequencing Targeted gene sequencing (e.g., AmpliSeq Cancer Panel 2.0) Q² Solutions Comprehensive Cancer Panel

About Q² Solutions

Launched in 2015, Q² Solutions is a leading global clinical trials laboratory services organization. We help biopharmaceutical, medical device and diagnostics customers improve human health through innovation that transforms science and data into actionable medical insights. Q² Solutions is a quality driven, responsive partner with strong global experience and deep scientific and medical expertise. The Q² Solutions joint venture was formed by QuintilesIMS and Quest Diagnostics, combining the best of each parent organization's clinical trials laboratory services capabilities.

Contact us

 Toll free:
 1 855.277.9929

 Direct:
 +1 919.998.7000

 International:
 +44 (0) 1506 814000

 Website:
 www.Q2LabSolutions.com

